User login
Key clinical point: Galcanezumab significantly reduced interictal burden, as measured by the 4-item Migraine Interictal Burden Scale (MIBS-4), in patients with episodic or chronic migraine and multiple prior migraine preventive treatment failures.
Major finding: At 3 months, the mean MIBS-4 score reduced significantly with galcanezumab vs placebo in the overall population (least-squares mean change [Δ] −1.9 vs −0.8; P < .0001) and in patients with episodic (Δ −1.8 vs −1.1; P = .033) and chronic (Δ −1.8 vs −0.3; P < .001) migraine.
Study details: This was a post hoc analysis of the CONQUER study including 462 patients with chronic or episodic migraine and multiple prior migraine preventive treatment failures who were randomly assigned to receive galcanezumab or placebo.
Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving research funding or support from various pharmaceutical sources, including Eli Lilly and Company. Some others declared being employees and minor stockholders of Eli Lilly and Company.
Source: Lipton RB et al. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study. Headache. 2023 (Feb 16). Doi: 10.1111/head.14460
Key clinical point: Galcanezumab significantly reduced interictal burden, as measured by the 4-item Migraine Interictal Burden Scale (MIBS-4), in patients with episodic or chronic migraine and multiple prior migraine preventive treatment failures.
Major finding: At 3 months, the mean MIBS-4 score reduced significantly with galcanezumab vs placebo in the overall population (least-squares mean change [Δ] −1.9 vs −0.8; P < .0001) and in patients with episodic (Δ −1.8 vs −1.1; P = .033) and chronic (Δ −1.8 vs −0.3; P < .001) migraine.
Study details: This was a post hoc analysis of the CONQUER study including 462 patients with chronic or episodic migraine and multiple prior migraine preventive treatment failures who were randomly assigned to receive galcanezumab or placebo.
Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving research funding or support from various pharmaceutical sources, including Eli Lilly and Company. Some others declared being employees and minor stockholders of Eli Lilly and Company.
Source: Lipton RB et al. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study. Headache. 2023 (Feb 16). Doi: 10.1111/head.14460
Key clinical point: Galcanezumab significantly reduced interictal burden, as measured by the 4-item Migraine Interictal Burden Scale (MIBS-4), in patients with episodic or chronic migraine and multiple prior migraine preventive treatment failures.
Major finding: At 3 months, the mean MIBS-4 score reduced significantly with galcanezumab vs placebo in the overall population (least-squares mean change [Δ] −1.9 vs −0.8; P < .0001) and in patients with episodic (Δ −1.8 vs −1.1; P = .033) and chronic (Δ −1.8 vs −0.3; P < .001) migraine.
Study details: This was a post hoc analysis of the CONQUER study including 462 patients with chronic or episodic migraine and multiple prior migraine preventive treatment failures who were randomly assigned to receive galcanezumab or placebo.
Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving research funding or support from various pharmaceutical sources, including Eli Lilly and Company. Some others declared being employees and minor stockholders of Eli Lilly and Company.
Source: Lipton RB et al. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study. Headache. 2023 (Feb 16). Doi: 10.1111/head.14460